Horizon Therapeutics Public Limited Company (HZNP): Shedding Light on Earning Per Share Reports


Horizon Therapeutics Public Limited Company (NASDAQ:HZNP) changes shares on Thursday trading session, with a change of -5.45% or -$4.16 shares. The trading starts at $75.20 and closed at $76.38 throughout the day. The trading session low price was $69.2017 and day high was $75.87 on Thursday, August 06. After the session, the Healthcare sector daily volume shifted to 5.37 million while its average volume is 2.71M. In other hand, the HZNP market cap reached to $13.97B. While, its current target price is $65.10.

On July 9, 2020, BRIEF-Horizon Therapeutics – CMS Issues Permanent J-Code For Tepezza Effective Oct 1. According to the news reported on Reuters, * HORIZON THERAPEUTICS PLC – CMS ISSUES PERMANENT J-CODE FOR TEPEZZA (TEPROTUMUMAB-TRBW) EFFECTIVE OCT. 1 Source text for Eikon: Further company coverage:

Checking out the performance report which defines the increase or decrease of prices for a specific period. For the last 5 trading sessions, its performance is up 16.43% and up 22.91% for month. Its quarterly performance was 71.83% above, while its half year performance is up 104.65%. HZNP yearly performance stood at positive 205.37% and rise 99.50% for year-to-date. Current recommendation for Horizon Therapeutics Public Limited Company is 1.70.

Earnings per share or EPS is an important financial measure, which defines the profitability of a company. HZNP EPS (TTM) for 12-month is 2.84. EPS for this year is 736.30%, while for the next year its value is 2.85. Sales growth for the current quarter is 1.40 while its EPS Q/Q reached 62.40%. It has an EPS of 23.90% up for past five years and for the next five years will be up 18.20%.

Let’s take a look on the analyst recommendations on HZNP for the current month and previous month. For the current month, 8 of 9 analysts recommend stock as Buy while 0 as Sell, 0 as overweight, 0 as underweight and 1 as Hold. As compared with the previous month ratings, 0 analysts participate in stock recommendation. Out of 0, 0 rated it sell, 0 rated it as Buy and 0 as Hold Ratings. On the other hand, target price ranges from $70.00 – $123.00. Average target price for HZNP was reached at $96.11.

The insider ownership moved to 0.70% and institutional holding shifted to 94.40%.

The company posted an EPS (TTM) of 2.84. According to the most recent quarter report on (Sep 2020), 9 analysts estimated an average EPS of 0.86, while 0.64 EPS posted a year ago period. Analyst Estimated EPS for HZNP published in the report was $0.53 – $1.13 during the same period. Comparing with last year, the average estimated EPS was 0.64 which is higher than 0.4 which was posted for recent quarter EPS.

A brief look on simple moving average (SMA) that determines the market price can impact a market. The SMA for HZNP rise 83.84% for period of 200 days. SMA for 50 days was 31.91% which is showing green signal, while SMA-20 was 20.72%. The moving average value for Horizon Therapeutics Public Limited Company (HZNP) is 42.24 and 57.47 for 200 and 50 days respectively.

Let’s take a look on the insider transactions, in which multiple shareholders are showing interest in HZNP stock. On Jul 22, GREY MICHAEL G, Director, sold 1,755 trading shares at the cost of $60.00, which valued at 0.11 million. On Jul 06, SHERMAN JEFFREY W, EVP and Chief Medical Officer, sold 9,100 shares at the cost of $57.50, with total shares of 278,797. On Jul 01, MOZE BARRY, EVP, Chief Admin. Officer, sold 23,158 shares at the cost of 54.64. After this transaction, MOZE BARRY total shares reached to 143,133 which valued at 1.27 million.